COATINGS
Antithrombogenic Coatings
- Introduction
- Antithrombotic coatings do not have to control the amount of thrombosis that should be classified by patient
- Advantages
- Safety
- Ease of use
- Reduce the risk of drug injection
- Visual inspection of ECMO tubes coated with antithrombogenic coating
- Visual inspection of tube after in vitro circulation for 48hr.
| Sample name | Tube | Connector | Cone head |
|---|---|---|---|
| Noanix |  |  |  |
| Competitor-A |  |  |  |
| Competitor-B |  |  |  |
| Sample name | Pump hour | LPM start | LPM end | Presence of thrombosis in priming solution | Intra-tube surface agglomeration | Thrombosis in the connector | Thrombosis in the cone head |
|---|---|---|---|---|---|---|---|
| Noanix | 48 | 7.2 | 7.2 | 1+ | – | – | ± |
| Competitor-A | 48 | 6.0 | 5.5 | – | 3+ | 2+ | 3+ |
| Competitor-B | 45 | 6.0 | 4.4 | – | 3+ | 2+ | 4+ |
- Fluorescence staining of ECMO tubes coated with antithrombogenic coating
- Platelet attachment to inner surface of tuve after in vitro circulation for 48hr.
- IF STAIN Confocal microscope inspection 40X
| Noanix | Competitor-A | Competitor-B | |||
|---|---|---|---|---|---|
 |  |  |  |  |  |
- SEM of ECMO tubes coated with antithrombogenic coating
- Platelet attachment to inner surface of tuve after in vitro circulation for 48hr.
| Noanix | Competitor-A | Competitor-B |
|---|---|---|
 |  |  |
| Sample name | Pump hour | the appearance of the coating being peeled off | Fibrin observation | Thrombus colony status | Presence of thrombosis |
|---|---|---|---|---|---|
| Noanix | 48 | 1+ | – | – | 1+ |
| Competitor-A | 48 | – | 4+ | 4+ | 4+ |
| Competitor-B | 45 | – | 3+ | 3+ | 3+ |
- Flow cytometry of ECMO tubes coated with antithrombogenic coating
| Sample name | Noanix | Competitor-A | Competitor-B | |||
|---|---|---|---|---|---|---|
| Graph |  |  |  |  |  |  |
| Total(%) CD61+ CD62P+ | 72.26 | 35.23 | 88.05 | 10.37 | 36.86 | 1.04 |
| Reduction ratio(%) | 51.2 | 88.2 | 97.2 | |||